This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (17)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Conflict of Interest  • Health Policy  • Patient-Physician Communication  • Alert me on articles by topic

A Haphazard Approach to Health Promotion

Matthew F. Hollon, MD, MPH

JAMA. 2005;293:2030-2033.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In JAMA 6 years ago, Holmer (then president of the Pharmaceutical Research and Manufacturers of America) and I published paired opinion pieces about the public health benefit of direct-to-consumer advertising (DTCA). Holmer wrote, "[DTCA] is an excellent way to meet the growing demand for medical information, empowering consumers by educating them about health conditions and possible treatments."¹ I countered that, "unlike the truly valuable contributions of the pharmaceutical industry, [DTCA] is not good for patients, physicians, or the public’s health."² Neither of us had much evidence to substantiate our arguments. We agreed that policymakers needed studies to determine more definitively the impact on public health.

In the intervening years, researchers have published a substantial body of literature on DTCA. The bulk of this work has been observational analysis and survey data of the $3.2-billion-per-year³ uncontrolled experiment with DTCA in the United States brought on by . . . [Full Text of this Article]

Author Affiliation: Department of Medicine, University of Washington, Seattle.

RELATED ARTICLE

Influence of Patients’ Requests for Direct-to-Consumer Advertised Antidepressants: A Randomized Controlled Trial
Richard L. Kravitz, Ronald M. Epstein, Mitchell D. Feldman, Carol E. Franz, Rahman Azari, Michael S. Wilkes, Ladson Hinton, and Peter Franks
JAMA. 2005;293(16):1995-2002.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of Ezetimibe in the United States and Canada
Jackevicius et al.
NEJM 2008;358:1819-1828.
ABSTRACT | FULL TEXT  

`I'd rather not take Prozac': stigma and commodification in antidepressant consumer narratives
Smardon
Health (London) 2008;12:67-86.
ABSTRACT  

News media coverage of direct-to-consumer pharmaceutical advertising: implications for countervailing powers theory
Hartley and Coleman
Health (London) 2008;12:107-132.
ABSTRACT  

Are Doctors Prepared for Direct-to-Consumer Advertising of Genetics Tests?
Tracy
Obstet Gynecol 2007;110:1389-1391.
FULL TEXT  

A Decade of Direct-to-Consumer Advertising of Prescription Drugs
Donohue et al.
NEJM 2007;357:673-681.
ABSTRACT | FULL TEXT  

The Fish in Secondary Prevention of Heart Disease (FISH) Survey--Primary Care Physicians and {omega}3 Fatty Acid Prescribing Behaviors
Oh et al.
J Am Board Fam Med 2006;19:459-467.
ABSTRACT | FULL TEXT  

"Your Life is Waiting!": Symbolic Meanings in Direct-to-Consumer Antidepressant Advertising
Grow et al.
Journal of Communication Inquiry 2006;30:163-188.
ABSTRACT  

Direct-to-Consumer Advertising in Oncology.
Abel et al.
The Oncologist 2006;11:217-226.
ABSTRACT | FULL TEXT  

Which Way For Competition? None Of The Above
Berenson
Health Aff (Millwood) 2005;24:1536-1542.
ABSTRACT | FULL TEXT  

Direct-to-Consumer Advertising and Physician Prescribing
Miller and Wendler
JAMA 2005;294:678-678.
FULL TEXT